Clinical Edge Journal Scan

Preoperative MRI may allow radiotherapy omission in some women with early BC


 

Key clinical point: Women with apparently unifocal, non–triple-negative breast cancer (BC) who underwent preoperative magnetic resonance imaging (MRI) and did not have any occult malignancy may safely forgo radiation therapy.

Major finding: Preoperative MRI detected malignant occult lesions in 11% of patients with BC. At 5 years, the ipsilateral invasive recurrence rate was very low (1.0%; upper 95% CI 5.4%) in patients with no occult malignancy who did not receive adjuvant radiotherapy.

Study details: Findings are from the prospective 2-arm PROSPECT study that included 443 patients with non–triple-negative, clinical stage T1N0, apparently unifocal BC who underwent MRI, of whom 201 patients underwent breast-conserving surgery without radiotherapy and 242 women were deemed ineligible for radiotherapy omission.

Disclosures: This study was funded by the Breast Cancer Trials, Australia, and other sources. The authors declared no conflicts of interest.

Source: Mann GB et al. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): Primary results of a prospective two-arm study. Lancet. 2023 (Dec 5). doi: 10.1016/S0140-6736(23)02476-5

Recommended Reading

Living in a Food Swamp Tied to High Breast Cancer Mortality
MDedge Hematology and Oncology
‘Baby TAM’ effective, tolerable for breast cancer prevention
MDedge Hematology and Oncology
Few with inflammatory breast cancer get guideline-based care
MDedge Hematology and Oncology
Less is more for axillary surgery in early breast cancer
MDedge Hematology and Oncology
Patients with HR-positive breast cancer can safely use ART
MDedge Hematology and Oncology
Pregnancy safe after BRCA-mutated breast cancer
MDedge Hematology and Oncology
Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer
MDedge Hematology and Oncology
Young BRCA carriers with BC history may safely opt for pregnancy
MDedge Hematology and Oncology
Pemetrexed + vinorelbine bests vinolrelbine monotherapy in metastatic BC in phase 2
MDedge Hematology and Oncology
Cholesterol-lowering interventions with statins may improve prognosis in BC
MDedge Hematology and Oncology